Yujiro Hata, Ideaya Biosciences CEO
July 8, 2024 07:29 AM EDTUpdated 08:59 AM
R&D

Ideaya show­cas­es proof-of-con­cept da­ta in a boost to syn­thet­ic lethal­i­ty play

Amber Tong

Fresh Phase 2 da­ta are adding weight to Ideaya Bio­sciences’ case for a tar­get­ed ther­a­py it be­lieves could be a first-in-class treat­ment op­tion for cer­tain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times